Reduction of Nasopharyngeal Carriage of Pneumococci during the Second Year of Life by a Heptavalent Conjugate Pneumococcal Vaccine

Children 12-18 months old were randomized to receive one dose of a conjugate heptavalent pneumococcal vaccine, two doses of the same vaccine, or one dose of a 23-valent native polysaccharide vaccine. Before immunization, pneumococci included in the conjugate vaccine were isolated from 24% of the chi...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1996-12, Vol.174 (6), p.1271-1278
Main Authors: Dagan, Ron, Melamed, Rimma, Muallem, Marie, Piglansky, Lolita, Greenberg, David, Abramson, Oren, Mendelman, Paul M., Bohidar, Norman, Yagupsky, Pablo
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Bacterial - analysis
Bacterial diseases
Bacterial diseases of the respiratory system
Bacterial Vaccines - administration & dosage
Bacterial Vaccines - immunology
Biological and medical sciences
Blood
Carrier State
Conjugate vaccines
Dosage
Drug Resistance, Microbial
Haemophilus influenzae type b
Human bacterial diseases
Humans
Immunization
Infant
Infectious diseases
Major Articles
Medical sciences
Nasopharyngitis - drug therapy
Nasopharyngitis - microbiology
Nasopharyngitis - prevention & control
Nasopharynx - microbiology
Pneumococcal Infections - drug therapy
Pneumococcal Infections - microbiology
Pneumococcal Infections - prevention & control
Pneumococcal vaccine
Pneumococcal Vaccines
Polysaccharides
Streptococcus pneumoniae
Streptococcus pneumoniae - growth & development
Streptococcus pneumoniae - immunology
Streptococcus pneumoniae - isolation & purification
Vaccination
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Children 12-18 months old were randomized to receive one dose of a conjugate heptavalent pneumococcal vaccine, two doses of the same vaccine, or one dose of a 23-valent native polysaccharide vaccine. Before immunization, pneumococci included in the conjugate vaccine were isolated from 24% of the children, and an antibiotic-resistant pneumococcus was isolated from 22% of the children. The vaccines had no effect on carriage of non - vaccine-type pneumococci. In contrast, there was a significant reduction in carriage of vaccine-type pneumococci 3 months after one dose and 1 month after a second dose of conjugate vaccine (from 25% to 9% and 7%, respectively; P < .001). No effect was seen after vaccination with the nonconjugate vaccine. One year after immunization, carriage of antibiotic-resistant vaccine-type pneumococci in children receiving conjugate vaccine was lower than that in children receiving the nonconjugate vaccine (4% vs. 14%, P = .042). Conjugate pneumococcal vaccines may reduce spread of pneumococci in the community.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/174.6.1271